RecruitingNot a traditional drug phaseobservationalRules rewrite

Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have symptoms that last long after the active infection ends.

Official registry: https://clinicaltrials.gov/study/NCT06577467 · National Institute of Neurological Disorders and Stroke (NINDS) · enrollment listed as 12

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 12 people at Bethesda. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

Primary outcome (registry wording): To determine where remnants of SARS-CoV-2 virus can be recovered in persons with neuro-PASC and RVs.

Who it is for (from inclusion criteria)

Ages 18 Years to 110 Years
Recovered Volunteers (RV): Six healthy persons who have recovered from an acute SARS-CoV-2 infection
who can join:
Participants 18 and older
Completed participation in Phase B of Protocol 000089
Met 000089 who can join for Mild to Moderate COVID-19 without PASC symptoms:
Licensed Independent Practitioner documentation of a stable state of general well-health and physical function prior to contracting SARS-CoV-2. This may include medical records, correspondence letters, or information gathered from telephone calls with study personnel
A self-reported illness narrative of recovery to prior health after a SARS/CoV2 infection

Who the registry excludes

Current suicidal ideation
Women who are pregnant, breastfeeding, or are within one-year post-partum
Current or previous malignancy. A history of malignancy that has fully resolved with surgical resection only (e.g. no chemotherapy, radiation therapy, or immunotherapy) will be allowed
Current systemic immunologic disorders (e.g. Type 1 diabetes, rheumatoid arthritis). Local immunological disorder (e.g. atopic dermatitis, stable autoimmune thyroid disease) and allergic disorders will be allowed
Current or previous long-term immune suppressive therapy. Systemic steroid use, even short-term, must not have been used within the month prior to enrollment
Long term use of anticoagulant or antiplatelet medications
Active participation in a clinical protocol (e.g. anti-inflammatory drug intervention study) which includes an intervention that may affect the results of the current study

Public study contact (from the registry)

Cynthia L Vierria

(301) 594-6760

cynthia.vierria@nih.gov

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

National Institutes of Health Clinical Center — Bethesda, Maryland (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSan Francisco, California

Long-term Impact of Infection With Novel Coronavirus (COVID-19)

LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data.

NCT04362150 · Official ClinicalTrials.gov record · University of California, San Francisco

RecruitingPhase 2Kaohsiung City

Phase 2: testing DAOIB for Long COVID

We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks.

NCT05764538 · Official ClinicalTrials.gov record · Chang Gung Memorial Hospital

RecruitingNot a traditional drug phasePaiporta, Valencia

Not a traditional drug phase: Transcranial Direct Current Therapy (tDCS) for COVID-19

This study aims to verify the how well it works/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and myalgia, as well as sleep problems. Transcranial direct current stimulation is used in the field of Physiotherapy and Rehabilitation, with results that have proven to be effective for treating patients suffering from symptoms like migraines, headaches, chronic pain, fibromyalgia, or chronic neuropathic pain and insomnia.

NCT05780450 · Official ClinicalTrials.gov record · Fundación Universidad Católica de Valencia San Vicente Mártir

FAQ about this NCT record

Is NCT06577467 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06577467?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06577467?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary